Abstract
This paper reviews clinical trials with physostigmine administered to Alzheimer patients using three different routes of administration: oral, i.v. and intracerebroventricular (i.c.v.). It compares results obtained with three different routes by the authors as well as by other authors. Particular emphasis is given to a novel type of physostigmine administration, the i.c.v. route. Advantages and disadvantages, as well as side effects of each route are presented and discussed.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Administration, Oral
-
Alzheimer Disease / blood
-
Alzheimer Disease / drug therapy*
-
Animals
-
Brain / drug effects
-
Brain / metabolism*
-
Butyrylcholinesterase / blood
-
Cholinergic Fibers / drug effects
-
Cholinergic Fibers / metabolism*
-
Cholinesterases / blood
-
Clinical Trials as Topic
-
Dose-Response Relationship, Drug
-
Injections, Intravenous
-
Injections, Intraventricular
-
Memory / drug effects
-
Physostigmine / administration & dosage
-
Physostigmine / therapeutic use*
Substances
-
Physostigmine
-
Butyrylcholinesterase
-
Cholinesterases